New Trends in Brain Shuttle Peptides

Overview

Journal Mol Pharm

Publisher American Chemical Society

Date 2025 Feb 3

PMID 39899901

Authors

Roger Prades

Meritxell Teixido

Benjami Oller-Salvia

Affiliations

Soon will be listed here.

Abstract

The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood-brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation.

Citing Articles

A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis.

Masmudi-Martin M, Oller-Salvia B, Perea M, Teixido M, Valiente M, Giralt E Mol Pharm. 2025; 22(3):1384-1395.

PMID: 39924896 PMC: 11881140. DOI: 10.1021/acs.molpharmaceut.4c01091.

References

Gregory J, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E . Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020; 11(1):5687. PMC: 7655867. DOI: 10.1038/s41467-020-19225-7. View

Liu J, Sun Y, Zeng X, Liu Y, Liu C, Zhou Y . Engineering and Characterization of an Artificial Drug-Carrying Vesicles Nanoplatform for Enhanced Specifically Targeted Therapy of Glioblastoma. Adv Mater. 2023; 35(41):e2303660. DOI: 10.1002/adma.202303660. View

Lucana M, Arruga Y, Petrachi E, Roig A, Lucchi R, Oller-Salvia B . Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics. 2021; 13(12). PMC: 8708026. DOI: 10.3390/pharmaceutics13122065. View

Al-Azzawi S, Masheta D, Guildford A, Phillips G, Santin M . Designing and Characterization of a Novel Delivery System for Improved Cellular Uptake by Brain Using Dendronised Apo-E-Derived Peptide. Front Bioeng Biotechnol. 2019; 7:49. PMC: 6443832. DOI: 10.3389/fbioe.2019.00049. View

Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R . Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155(2):185-97. PMC: 2538693. DOI: 10.1038/bjp.2008.260. View

Ge J, Tan R, Gao Q, Li R, Xu P, Song H . A Multifunctional Nanocarrier System for Highly Efficient and Targeted Delivery of Ketamine to NMDAR Sites for Improved Treatment of Depression. Adv Healthc Mater. 2023; 12(21):e2300154. DOI: 10.1002/adhm.202300154. View

Woythe L, Tito N, Albertazzi L . A quantitative view on multivalent nanomedicine targeting. Adv Drug Deliv Rev. 2020; 169:1-21. DOI: 10.1016/j.addr.2020.11.010. View

Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P . Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014; 81(1):49-60. DOI: 10.1016/j.neuron.2013.10.061. View

Lee J, Engler J, Collawn J, Moore B . Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 2001; 268(7):2004-12. DOI: 10.1046/j.1432-1327.2001.02073.x. View

10.

Oller-Salvia B, Sanchez-Navarro M, Giralt E, Teixido M . Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev. 2016; 45(17):4690-707. DOI: 10.1039/c6cs00076b. View

11.

Yeoh Y, Amin A, Cuic B, Tomas D, Turner B, Shabanpoor F . Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide. Biomed Pharmacother. 2024; 175:116737. DOI: 10.1016/j.biopha.2024.116737. View

12.

Spengler J, Jimenez J, Burger K, Giralt E, Albericio F . Abbreviated nomenclature for cyclic and branched homo- and hetero-detic peptides. J Pept Res. 2005; 65(6):550-5. DOI: 10.1111/j.1399-3011.2005.00254.x. View

13.

Rao K, Reddy M, Horning J, Labhasetwar V . TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008; 29(33):4429-38. PMC: 2570783. DOI: 10.1016/j.biomaterials.2008.08.004. View

14.

Ying M, Wang S, Zhang M, Wang R, Zhu H, Ruan H . Myristic Acid-Modified A7R Peptide for Whole-Process Glioma-Targeted Drug Delivery. ACS Appl Mater Interfaces. 2018; 10(23):19473-19482. DOI: 10.1021/acsami.8b05235. View

15.

Guo Q, Zhu Q, Miao T, Tao J, Ju X, Sun Z . LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. J Control Release. 2019; 303:117-129. DOI: 10.1016/j.jconrel.2019.04.031. View

16.

Eiselt E, Otis V, Belleville K, Yang G, Larocque A, Regina A . Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain. J Pharmacol Exp Ther. 2020; 374(1):52-61. DOI: 10.1124/jpet.119.263566. View

17.

Daneman R, Zhou L, Agalliu D, Cahoy J, Kaushal A, Barres B . The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One. 2010; 5(10):e13741. PMC: 2966423. DOI: 10.1371/journal.pone.0013741. View

18.

Muttenthaler M, King G, Adams D, Alewood P . Trends in peptide drug discovery. Nat Rev Drug Discov. 2021; 20(4):309-325. DOI: 10.1038/s41573-020-00135-8. View

19.

Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S . Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. Adv Sci (Weinh). 2022; 9(17):e2105451. PMC: 9189685. DOI: 10.1002/advs.202105451. View

20.

Sierri G, Patrucco M, Ferrario D, Renda A, Comi S, Ciprandi M . Targeting specific brain districts for advanced nanotherapies: A review from the perspective of precision nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(5):e1991. PMC: 11670049. DOI: 10.1002/wnan.1991. View